🧬 Tantti specializes in macroporous chromatography beads. These beads enhance the purification of large molecule biologics.
📈 Repligen’s CEO emphasizes the acquisition will boost high-capacity purification solutions.
🔜 The deal is expected to finalize in Q4 2024.
👥 Both companies are excited about this growth opportunity in bioprocessing.
Introduction:
Repligen, a prominent player in the bioprocessing sector, has announced its strategic acquisition of Tantti Laboratory, marking a significant step in expanding its portfolio for purification technologies. This acquisition aims to enhance capabilities in processing complex biological materials necessary for modern therapeutic production.
- Repligen has entered into a definitive agreement to acquire privately-held Tantti Laboratory, based in Taiwan.
- Tantti has developed macroporous chromatography beads that optimize the purification process for new modalities, including viral vectors and large molecule biologics.
- The DuloCore® technology platform from Tantti integrates high throughput performance with rapid mass transfer, offering improved efficiencies in purification.
- The acquisition highlights Repligen’s commitment to advancing high-capacity purification products, which are crucial for bioprocessing manufacturers.
- The transaction is expected to finalize in the fourth quarter of 2024, positioning Repligen to integrate and leverage Tantti’s innovative technology for enhanced market presence.
Conclusion:
This acquisition signifies Repligen’s proactive strategy to strengthen its bioprocessing capabilities amidst growing demands for efficient purification solutions. By integrating Tantti’s advanced technology, Repligen aims to address key industry challenges while bolstering its market position and capacity to meet future biopharma needs.
